File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients

TitleUpdated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients
Authors
Issue Date2010
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.translational-medicine.com/home/
Citation
Journal Of Translational Medicine, 2010, v. 8 How to Cite?
AbstractBackground: Bortezomib, an NFkB inhibitor, is an active agent for the treatment of myeloma (MM). We have reported a promising complete remission (CR) rate for newly diagnosed myeloma patients treated by a staged approach, in which chemosensitive patients underwent autologous haematopoietic stem cell transplantation (auto-HSCT) while less chemosensitive patients received salvage therapy with bortezomib/thalidomide/dexamethasone prior to auto-HSCT.Methods: Herein, with an additional 13 months of follow-up, we reported the updated survivals, and examined potential prognostic factors impacting event-free (EFS) and overall survival (OS).Results: With a median follow-up of 30 months, the projected OS was 73% and EFS was 50.2%. Age, gender, clinical stage and DAPK methylation could not account for the differential chemosensitivity. Advanced ISS stage and DAPK methylation adversely impacted OS whereas oligoclonal reconstitution predicted superior EFS.Conclusions: Our staged approach illustrated an economical use of expensive targeted agents while preserving a good CR rate and OS. The comparable survivals of chemosensitive and less chemosensitive patients suggested the staged approach might have abolished the adverse prognostic impact of suboptimal chemosensitivity. Finally, the adverse impact of DAPK methylation and favorable impact of oligoclonal reconstitution in myeloma warrants further study. © 2010 Chim; licensee BioMed Central Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/124917
ISSN
2015 Impact Factor: 3.694
2015 SCImago Journal Rankings: 1.766
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChim, CSen_HK
dc.date.accessioned2010-10-31T11:01:24Z-
dc.date.available2010-10-31T11:01:24Z-
dc.date.issued2010en_HK
dc.identifier.citationJournal Of Translational Medicine, 2010, v. 8en_HK
dc.identifier.issn1479-5876en_HK
dc.identifier.urihttp://hdl.handle.net/10722/124917-
dc.description.abstractBackground: Bortezomib, an NFkB inhibitor, is an active agent for the treatment of myeloma (MM). We have reported a promising complete remission (CR) rate for newly diagnosed myeloma patients treated by a staged approach, in which chemosensitive patients underwent autologous haematopoietic stem cell transplantation (auto-HSCT) while less chemosensitive patients received salvage therapy with bortezomib/thalidomide/dexamethasone prior to auto-HSCT.Methods: Herein, with an additional 13 months of follow-up, we reported the updated survivals, and examined potential prognostic factors impacting event-free (EFS) and overall survival (OS).Results: With a median follow-up of 30 months, the projected OS was 73% and EFS was 50.2%. Age, gender, clinical stage and DAPK methylation could not account for the differential chemosensitivity. Advanced ISS stage and DAPK methylation adversely impacted OS whereas oligoclonal reconstitution predicted superior EFS.Conclusions: Our staged approach illustrated an economical use of expensive targeted agents while preserving a good CR rate and OS. The comparable survivals of chemosensitive and less chemosensitive patients suggested the staged approach might have abolished the adverse prognostic impact of suboptimal chemosensitivity. Finally, the adverse impact of DAPK methylation and favorable impact of oligoclonal reconstitution in myeloma warrants further study. © 2010 Chim; licensee BioMed Central Ltd.en_HK
dc.languageengen_HK
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.translational-medicine.com/home/en_HK
dc.relation.ispartofJournal of Translational Medicineen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsJournal of Translational Medicine. Copyright © BioMed Central Ltd.-
dc.subject.meshAntineoplastic Agents - therapeutic use-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic use-
dc.subject.meshBoronic Acids - therapeutic use-
dc.subject.meshDexamethasone - therapeutic use-
dc.subject.meshMultiple Myeloma - drug therapy - enzymology - pathology-
dc.titleUpdated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1479-5876&volume=8&issue=124&spage=&epage=&date=2010&atitle=Updated+survivals+and+prognostic+factor+analysis+in+myeloma+treated+by+a+staged+approach+use+of+bortezomib/thalidlomide/dexamethasone+in+transplant+eligible+patientsen_HK
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/1479-5876-8-124en_HK
dc.identifier.pmid21108845-
dc.identifier.pmcidPMC3003638-
dc.identifier.scopuseid_2-s2.0-78649327381en_HK
dc.identifier.hkuros175486en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78649327381&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume8en_HK
dc.identifier.issue124-
dc.identifier.isiWOS:000285468700001-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.citeulike8382611-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats